Advertisement

Topics

Search Results for "Where To Buy Pirfenidone"

10:12 EST 22nd February 2017 | BioPortfolio

Matching Channels

None

Matching News

NICE rejects expanded treatment indication for Roche's Esbriet

NICE has published a final appraisal rejecting the expanded use of Roche’s Esbriet (pirfenidone) for the treatment of early idiopathic pulmonary fibrosis (IPF) in the UK. Roche said the decision lea...

ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial

Early evidence of efficacy of PBI-4050 alone and also in combination with one of the commercially available IPF drugs PBI-4050 shown to be very well tolerated whether used alone or in combi...

Global Idiopathic Pulmonary Fibrosis 20162020 Prices from USD $2500

About Idiopathic Pulmonary FibrosisIdiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 5070 years. Diagnosis is ef...

Matching PubMed Articles

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This study was designed to ev...

Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia.

Desmoplasia in human pancreatic cancer (PC) promotes cancer progression and hinders effective drug delivery. The objectives of this study were to characterize a homologous orthotopic model of PC in Sy...

Recent Advances and Future Needs in Interstitial Lung Diseases.

Interstitial lung diseases (ILDs) are a diverse range of conditions affecting the lung interstitium. The prototypic ILD, idiopathic pulmonary fibrosis (IPF), is a chronic progressive fibrotic lung dis...

Targeting coagulation factor receptors - protease-activated receptors in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with a 5-year mortality rate above 50% and unknown etiology. Treatment options remain limited and, currently, only two drugs are available,...

A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder showcasing an interaction between genetic predisposition and environmental risks. This usually involves the coa...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement